What does CUSIP 08659B102 represent in this 13F holders report?

CUSIP 08659B102 is the security identifier for BBNX - Beta Bionics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held BBNX - Beta Bionics, Inc. - Common Stock in Q1 2026?

13 institutional investors reported BBNX - Beta Bionics, Inc. - Common Stock for Q1 2026. Use the holders table for investor-level position and value details.

Beta Bionics, Inc. - Common Stock (BBNX)

CUSIP: 08659B102

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock
Shares outstanding: 44,038,904
Total 13F shares: 567,939
Share change: +305,723
Total reported value: $5,690,743
Price per share: $10.02
Number of holders: 13
Value change: -$643,935
Number of buys: 6
Number of sells: 9

Quarterly Holders Quick Answers

What is CUSIP 08659B102?
CUSIP 08659B102 identifies BBNX - Beta Bionics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 08659B102:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Top shareholders of BBNX - Beta Bionics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
EVENTIDE ASSET MANAGEMENT, LLC	13F 13D/G	Company	11% from 13D/G	4,994,728	$152,232,937	—	31 Dec 2025	13F 13D/G
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	9.8%	4,313,920	$131,445,142	—	31 Dec 2025	13F
Sands Capital Alternatives, LLC	13F	Company	8.1%	3,570,113	$108,781,343	—	31 Dec 2025	13F
MORGAN STANLEY	13F 13D/G	Company	8.6% from 13D/G	3,459,453	$105,409,532	—	31 Dec 2025	13F 13D/G
BlackRock, Inc.	13F 13D/G	Company	6.4% from 13D/G	2,913,920	$88,787,143	—	31 Dec 2025	13F 13D/G
Farallon Capital Partners, L.P.	13D/G	Dapice Joshua J.	9.9%	4,379,920	$88,211,589	+$3,544,640	31 Dec 2025	13D/G
Zone Healthcare Holdings, LLC	13D/G	Dapice Joshua J.	9.9%	4,313,920	$85,717,590	+$17,618,729	30 Sep 2025	13D/G
Soleus Capital Management, L.P.	13F	Company	5.8%	2,534,565	$77,228,196	—	31 Dec 2025	13F
RTW INVESTMENTS, LP	13F 13D/G	Company	5.7% from 13D/G	2,500,000	$76,175,000	—	31 Dec 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	5%	2,218,238	$67,589,712	—	31 Dec 2025	13F
Sands Capital Life Sciences Pulse Fund II, L.P.	13D/G	—	8.2%	3,570,113	$48,410,732	+$5,636,946	30 Jun 2025	13D/G
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	13F	Company	3%	1,327,100	$40,436,737	—	31 Dec 2025	13F
Omega Fund Management, LLC	13F	Company	3%	1,316,183	$40,104,096	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13D/G 13F	Company	5.2%	2,290,023	$34,190,043	$0	18 Feb 2026	13D/G 13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	2.2%	956,784	$29,153,208	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F 13D/G	Company	1.8% from 13D/G	945,461	$28,808,197	—	31 Dec 2025	13F 13D/G
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	2.1%	938,308	$28,590,245	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	2.1%	921,464	$28,083,886	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	2%	863,133	$26,299,663	—	31 Dec 2025	13F
PERCEPTIVE ADVISORS LLC	13D/G 13F	Company	3.7%	1,593,608	$21,609,324	$0	31 Mar 2025	13D/G 13F
Eversept Partners, LP	13F	Company	1.5%	678,262	$20,666,643	—	31 Dec 2025	13F
Walleye Capital LLC	13F	Company	1.5%	646,539	$19,700,043	—	31 Dec 2025	13F
Vestal Point Capital, LP	13F	Company	1.4%	600,000	$18,282,000	—	31 Dec 2025	13F
12 West Capital Management LP	13F	Company	1.3%	575,000	$17,520,250	—	31 Dec 2025	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	1.2%	532,749	$16,233,000	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.98%	432,340	$13,173,400	—	31 Dec 2025	13F
LORD, ABBETT & CO. LLC	13F	Company	0.98%	430,403	$13,114,000	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.93%	410,603	$12,511,073	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.92%	405,408	$12,352,781	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.79%	348,671	$10,624,005	—	31 Dec 2025	13F
NORGES BANK	13F	Company	0.77%	339,300	$10,338,471	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.75%	331,623	$10,104,553	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.73%	320,880	$9,777,214	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.65%	284,453	$8,667,283	—	31 Dec 2025	13F
PURA VIDA INVESTMENTS, LLC	13F	Company	0.64%	281,250	$8,569,688	—	31 Dec 2025	13F
TUDOR INVESTMENT CORP ET AL	13F	Company	0.59%	259,632	$7,910,987	—	31 Dec 2025	13F
First Eagle Investment Management, LLC	13F	Company	0.58%	253,702	$7,730,300	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.57%	251,438	$7,661,316	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	0.52%	227,956	$6,945,820	—	31 Dec 2025	13F
ESSEX INVESTMENT MANAGEMENT CO LLC	13F	Company	0.49%	217,796	$6,636,244	—	31 Dec 2025	13F
RAYMOND JAMES FINANCIAL INC	13F	Company	0.45%	197,939	$6,318,456	—	31 Dec 2025	13F
Russell Investments Group, Ltd.	13F	Company	0.47%	205,837	$6,271,866	—	31 Dec 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.46%	201,892	$6,151,649	—	31 Dec 2025	13F
Sean Saint	3/4/5	President & CEO, Director	— mixed-class rows	725,753 mixed-class rows	$5,412,019	-$221,050	27 Feb 2026	3/4/5
Steven Jon Russell	3/4/5	Chief Medical Officer	— mixed-class rows	269,591 mixed-class rows	$5,223,873	-$67,804	27 Feb 2026	3/4/5
VOLORIDGE INVESTMENT MANAGEMENT, LLC	13F	Company	0.34%	151,647	$4,620,684	—	31 Dec 2025	13F
SG Americas Securities, LLC	13F	Company	0.34%	150,277	$4,579,000	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.32%	140,592	$4,283,839	—	31 Dec 2025	13F
Freestone Grove Partners LP	13F	Company	0.31%	138,138	$4,209,065	—	31 Dec 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.31%	137,200	$4,180,484	—	31 Dec 2025	13F

Institutional Holders of Beta Bionics, Inc. - Common Stock (BBNX) as of Q1 2026

As of 31 Mar 2026, Beta Bionics, Inc. - Common Stock (BBNX) was held by 13 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 567,939 shares. The largest 10 holders included Y-Intercept (Hong Kong) Ltd, Values First Advisors, Inc., Evanson Asset Management, LLC, CoreCap Advisors, LLC, GAMMA Investing LLC, Sterling Capital Management LLC, Farther Finance Advisors, LLC, Versant Capital Management, Inc, Blue Trust, Inc., and True Wealth Design, LLC. This page lists 13 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

158

Q1 2026 holders

Holder diff

-145

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.